Prehypertension (PHTN) is a global health problem that carries the risk of being prone to developing hypertension in the future along with double the risk of cardiovascular disease (CVD). Its prevalence is 25 to 50% based on data from different countries, and it varies with age, sex, birth weight, and body mass index (BMI). Regarding its pathophysiology, several mechanisms have been proposed, but the most validated are Ras activation, oxidative stress, inflammatory cytokines, sympathetic overdrive, and central nervous system activation. Therapeutic lifestyle changes are the foundation for all therapies in prehypertensive patients, which are recommended by almost all guidelines. Drug therapy has also been tried in a couple of trials and is recommended in high-risk patients.
INTRODUCTION
In 1939, Robinson and Brucer suggested the value of clinically overt hypertension when the levels are 120 to 139 mm Hg (systolic) and 80 to 89 mm Hg (diastolic). 1 Three decades later, it was termed as "borderline hypertension"; 2 then in 1997, it was changed to "high-normal blood pressure (BP)." 3 The term "PHTN" was coined in
2003 by the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). 1 This report intended to identify those individuals in whom early intervention by healthy lifestyles could reduce BP and the rate of converting from PHTN to hypertension. The PHTN precedes clinical hypertension and is associated with increased incidence of CVD.
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DEFINITION
The PHTN is defined as a systolic BP (SBP) of 120 to 139 mm Hg and/or a diastolic BP of 80 to 89 mm Hg.
Later on, the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) bifurcated it into normal (120-129 systolic and 80-84 diastolic) and high-normal (130-139 systolic and 85-89 diastolic). The ESH-ESC committee decided against using the term "PHTN" for several reasons:
• There is no reason to combine the two different groups because the risk of developing hypertension was definitely higher in those with high-normal BP than in patients with normal BP. • The term "PHTN" can create anxiety in many subjects along with unnecessary medical visits and tests.
• Although lifestyle changes are recommended by the JNC7 for all PHTNs, this category is a highly differentiated one, with the extremes consisting of subjects with no need of any intervention.
PREVALENCE
The National Health and Nutrition Examination Survey (NHANES), 1999-2000 reported that the overall prevalence of PHTN was 31% all over the world, which was higher in men than in women. 5 A statistical analysis of disease-free adult NHANES participants, which was conducted from 1999 to 2006, found that the overall prevalence of PHTN in disease-free adults was 36.3%. 6 Prevalence increases in people with 7 • Diabetes, • Microalbuminuria, • Chronic kidney disease (CKD), • Heavy alcohol consumption, and • Overweight/obese.
Prevalence in India
In a study from northern India, the reported prevalence of PHTN is 44%, 8 whereas a study in urban Chennai indicated a 47% prevalence of PHTN in adults >18 years. 9 In another study, the reported prevalence is 40% in males and 30% in females. 10 The statewise prevalence in India is shown in Graph 1.
RISK FACTORS
The risk factors are indicated in Table 1 .
WHY CARE FOR PHTN
Patients with PHTN are at twice the risk of developing hypertension. 11 The PHTN is also associated with increased CVD. According to the Framingham study, there is increased risk of myocardial infarction by 3.5 fold and an increased risk of coronary artery disease by 1.7 fold 11 (Graph 2).
Results from the Strong Heart Study 12 showed an increased risk of CV events when PHTN is associated with diabetes compared with diabetes or PHTN alone (Graph 3).
The study also showed that 37% of prehypertensives will progress to hypertension over the next 4 years. There is a 2-fold increased risk of diabetes also in PHTN. Compared with a normal BP, PHTN is associated with a 27% increase in all causes of death and a 66% increase in cardiovascular deaths. 13 Analysis from the CARDIA study suggests that PHTN in early adulthood leads to increased coronary calcium later in life.
14 The PHTN is also associated with increased carotid intima thickness. 15 There is increase in left ventricular (LV) mass index also with PHTN 16 (Graph 4).
It is also associated with increased risk of CKD.
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A study also showed the worsening of renal function by 11 to 91% in prehypertensive individuals. Preexisting diabetes showed a strong relationship of PHTN and CKD risk. The basic pathophysiology for the development of CKD is the greater degree of renal arteriosclerosis and mesangial proliferation in prehypertensives. 17 High-normal BP is associated with poor cognitive performance also. The relationship between BP and cognitive 
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performance is linear, even in normotensive and prehypertensive ranges. 18 The PHTN also predicts pregnancyinduced hypertension and its postpartum progression. 19 The PHTN is also linked with metabolic syndrome and CVD (Flow Chart 1).
PATHOPHYSIOLOGY
Many hypotheses are proposed to explain the underlying pathophysiology of PHTN.
• (Table 3) , which uses a diet rich in fruits, vegetables, legumes, nuts, and low-fat dietary products and low saturated fats, has a significant lowering of BP. The DASH diet can reduce BP by 8 to 14 mm Hg, an effect that was augmented even further when dietary sodium was restricted. behavioral interventions with and without the DASH diet produced significant reductions in the 10-year risk of coronary heart disease in subjects with PHTN.
PHARMACOTHERAPY
The primary approach to treat PHTN is therapeutic lifestyle changes, which have been recommended by several guidelines. Pharmacotherapy is recommended mainly in high-risk groups with CVD and CKD. However, there is still no consensus. Few trials have been done with different pharmacological agents with mixed results. The Trial of Preventing Hypertension (TROPHY) study evaluated the effect of angiotensin II receptor antagonist candesartan cilexetil on the prevention of PHTN progressing to stage 1 hypertension 25 (Graph 6). After 4 years, stage 1 hypertension developed in two-thirds of patients in the placebo group, while in the intervention group, there was 66% reduction in the risk of development of incident hypertension.
The PHARAO study is the prevention of hypertension with the angiotensin-converting enzyme inhibitor Ramipril in patients with high-normal BP-a prospective, randomized, controlled prevention trial of the German Hypertension League. 26 The study showed significant reduction in the risk of progression to manifest hypertension by 34.4%. The PREVER prevention trial 27 is the combination of chlorthalidone and amiloride in prehypertensive patients that effectively reduces the risk of incident hypertension and beneficially affects LV mass. After 18 months, the incidence of hypertension was 11.7% in the diuretic arm vs 19.5% in the placebo arm.
Follow-up of Prehypertensive Patients
Subjects with PHTN need to be treated and evaluated every month or two, until the BP goal is reached and then every 3 to 6 months thereafter. Subjects with complications/end organ damage, such as heart or kidney disease may need to be evaluated more frequently at regular intervals.
CONCLUSION
• Prehypertension is a common problem in the community.
• Its prevalence is on the rise.
• It is associated with increased risk of hypertension, target organ damage, and CVD. • Healthy lifestyle is the foundation for all therapies in persons with PHTN. • Drug therapies have been tried, but there is no convincing evidence that antihypertensive therapy changes the course of PHTN. 
